Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotran...
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan, China
Qinghai University Affiliated Hospital, Xining, Qinghai, China
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Asan Medical Center, Seoul, Korea, Republic of
Seoul National University Hospital, Seoul, Korea, Republic of
Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
Eunah Cho, Seoul, Korea, Republic of
Asan Medical Center, Seoul, Korea, Republic of
Seoul National University Bundang Hospital, Seongnam-si, Gyunggi-do, Korea, Republic of
Gangnam Severance Hospital, Seoul, Korea, Republic of
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.